Oncolytics Reports Accelerating Enrollment in Colorectal Cancer Trial, Interim Data Expected by Year-End

Oncolytics Biotech Inc. announced accelerating patient enrollment for its randomized REO 033 study evaluating its lead drug, pelareorep, in second-line metastatic colorectal cancer (mCRC). With nearly all clinical sites now activated, the company expects to provide an interim clinical update from Part A of the study by the end of 2026.

Key Details

• Trial Update: The REO 033 study is evaluating pelareorep combined with FOLFIRI and bevacizumab versus the standard-of-care regimen alone in patients with RAS-mutant, MSS mCRC.
• Upcoming Milestone: The company anticipates having sufficient data to report an interim clinical update from Part A, which is expected to enroll approximately 60 patients, by year-end 2026.
• Regulatory Path: Oncolytics has aligned with the FDA on a potential path to accelerated approval based on Objective Response Rate (ORR) and full approval based on Progression-Free Survival (PFS), contingent on study results.